Fundraising FoxCapricor Therapeutics
NASDAQ: CAPRLos Angeles, US · 1 known investors
Find your way into Capricor Therapeutics
Sign up to see every warm intro you have to Capricor Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Capricor Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Capricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Founders & leadership
LM
LM
Linda Marbán, Ph.D.Chief Executive Officer and Director; co-founder of Capricor, Inc.
AB
Anthony BergmannExecutive
AH
Andrew HamerVice President of Medical Affairs2013–2015Andrew Hamer has over 20 years of experience as a practicing cardiologist and clinical trialist in New Zealand, followed by more than 12 years in biotech development roles. He has led global development initiatives for cardiometabolic products across multiple stages and managed clinical operations, regulatory affairs, and medical affairs functions for both small and large organizations.
Board
JK
Joshua KazamBoard director
DM
David MusketBoard director
LM
Louis ManzoBoard director
EC
Earl Collier, Jr.Board director
GS
Gregory SchaferBoard director
GD
George DunbarBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$25.3M disclosed across 6 of 7 rounds · 1900–2017
▶$3.7MraisedMay 2017 · 4 investors · BiotechnologyRule 506(b)
▶$3.7MraisedMay 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank LitvackDirector
- Deborah AscheimExecutive Officer
- Leland GershellExecutive Officer
- Earl CollierDirector
- Joshua KazamDirector
- Louis ManzoDirector
- Rachel SmithExecutive Officer
- Karen KrasneyExecutive Officer
- Linda MarbanExecutive Officer, Director
- David MusketDirector
- George DunbarDirector
- Anthony BergmannExecutive Officer
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14KraisedMar 2016 · 24 investors · BiotechnologyRule 506(b)
▶$14KraisedMar 2016 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Louis GrasmickDirector
- Linda MarbanExecutive Officer, Director
- Deborah AscheimExecutive Officer
- Louis ManzoDirector
- Anthony BergmannExecutive Officer
- Joshua KazamDirector
- Gregory SchaferDirector
- Frank LitvackDirector
- Rachel SmithExecutive Officer
- Leland GershellExecutive Officer
- David MusketDirector
- Earl Collier, Jr.Director
- Karen KrasneyExecutive Officer
- George DunbarDirector
- Offering amount
- $14K
- Amount sold
- $14K
- Placement agents
- SC&H Capital
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.1MraisedFeb 2015 · 8 investors · BiotechnologyRule 506(b)
▶$7.1MraisedFeb 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Earl Collier, Jr.Director
- Joshua KazamDirector
- Karen KrasneyExecutive Officer
- Gregory SchaferDirector
- George DunbarDirector
- David MusketDirector
- Louis GrasmickDirector
- Rachel SmithExecutive Officer
- Frank LitvackDirector
- Anthony BergmannExecutive Officer
- Andrew HamerExecutive Officer
- Louis ManzoDirector
- Linda MarbanExecutive Officer, Director
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- Sales commissions
- $364.5K
- Placement agents
- H.C. Wainwright & Co., LLC, SC&H Capital
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedFeb 2015 · 39 investors · BiotechnologyRule 506(b)
▶$10MraisedFeb 2015 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joshua KazamDirector
- Louis ManzoDirector
- Earl Collier, Jr.Director
- Rachel SmithExecutive Officer
- Louis GrasmickDirector
- Karen KrasneyExecutive Officer
- Gregory SchaferDirector
- Anthony BergmannExecutive Officer
- George DunbarDirector
- Frank LitvackDirector
- David MusketDirector
- Linda MarbanExecutive Officer, Director
- Andrew HamerExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $126.9K
- Placement agents
- H.C. Wainwright & Co., LLC, SC&H Capital
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$32.7KraisedFeb 2014 · 1 investors · Biotechnology
▶$32.7KraisedFeb 2014 · 1 investors · Biotechnology
Officers, directors & promoters on the filing
- Linda MarbanExecutive Officer, Director
- Frank LitvackDirector
- Karen KrasneyExecutive Officer
- Rachel SmithExecutive Officer
- Andrew HamerExecutive Officer
- George DunbarDirector
- Louis ManzoDirector
- Anthony BergmannExecutive Officer
- Joshua KazamDirector
- Gregory SchaferDirector
- David MusketDirector
- Louis GrasmickDirector
- Earl Collier, Jr.Director
- Offering amount
- $32.7K
- Amount sold
- $32.7K
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 05
▶$4.5MraisedJan 2012 · 3 investors · BiotechnologyRule 506(b)
▶$4.5MraisedJan 2012 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Linda S. MarbanExecutive Officer, Director
- Louis GrasmickDirector
- Louis V. ManzoDirector
- Earl M. Collier, Jr.Director
- Offering amount
- $15M
- Amount sold
- $4.5M
- Minimum investment
- $250K
- Proceeds to insiders
- $200K
- First sale
- Jan 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $794.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $124.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Capricor Therapeutics do?
- Capricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
- Who founded Capricor Therapeutics?
- Capricor Therapeutics was founded by Linda Marban, Linda Marbán, Ph.D..
- Who are Capricor Therapeutics's investors?
- Capricor Therapeutics's investors include Broadview Ventures.
- How much funding has Capricor Therapeutics raised?
- Capricor Therapeutics has disclosed $25.3M raised across 6 of its 7 known rounds.
- Where is Capricor Therapeutics headquartered?
- Capricor Therapeutics is headquartered in Los Angeles, US.